Article
Crystal structure of adenosine A2A receptor in complex with clinical candidate Etrumadenant reveals novel antagonist interaction
2023-02-27
Abstract excerpt
<title>Abstract</title><p>The G<sub>s</sub>-protein-coupled adenosine A<sub>2A</sub>receptor (A<sub>2A</sub>AR) represents an emerging drug target for cancer immunotherapy. The clinical candidate Etrumadenant was developed as an A<sub>2A</sub>AR antagonist with ancillary blockade of the A<sub>2B</sub>AR subtype. It constitutes a novel chemotype featuring a poly-substituted 2-amino-4-phenyl-6-triazolylpyrimidine co...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- b2d13f11-629b-5dcf-84cf-d3df96f4ef09
- DOI
- 10.21203/rs.3.rs-2602909/v1
